-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the Zhitong Finance App, Boan Biotech (06955.HK) announced that BA1302, an innovative antibody conjugate drug (ADC) targeting CD228 independently developed by the company, has completed the single-drug dose escalation phase (Phase Ia) of phase I clinical research in China. Research results showed that BA1302 showed good anti-tumor activity in patients with various advanced solid tumors whose disease progressed even after multi-line treatment, and the overall safety and tolerability was good.

Zhitongcaijing·08/14/2026 14:33:12
Listen to the news
According to the Zhitong Finance App, Boan Biotech (06955.HK) announced that BA1302, an innovative antibody conjugate drug (ADC) targeting CD228 independently developed by the company, has completed the single-drug dose escalation phase (Phase Ia) of phase I clinical research in China. Research results showed that BA1302 showed good anti-tumor activity in patients with various advanced solid tumors whose disease progressed even after multi-line treatment, and the overall safety and tolerability was good.